Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Type 1 Diabetes

In brief

The proposed study is designed to test the hypothesis that treatment of resveratrol for 12 weeks will improve both endothelin-B receptor (aim 1) and skeletal muscle mitochondrial function (aim 2) in people with type 1 diabetes.

Key facts

Study ID

NCT04449198

Run by

Augusta University

People needed

24

Starts

2020-10-14

Expected to finish

2027-07-01

Last updated by the study team

2025-01-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and premenopausal women
• All races
• Clinical diagnosis of insulin-dependent type 1 diabetes (patients only)

You may not qualify if…

• Clinical diagnosis of hepatic, cardiovascular, or renal disease
• Uncontrolled diabetes (HbA1C >12%)
• Diabetic complications (i.e. neuropathy)
• Uncontrolled hypertension (>140/90 mm Hg on therapy)
• Pregnancy
• Use of vasoactive medications

Where it is running

• Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology — Augusta, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.